

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7468005

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
VIKTORIIA KYRYCHENKO	07/28/2022
WAI LUN LEUNG	07/22/2022
PATRICK CLAUDIO OVANDO ROCHE	07/30/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CRISPR THERAPEUTICS AG
<b>Street Address:</b>	BAARERSTRASSE 14
<b>City:</b>	ZUG
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	6300
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17538719
Application Number:	63250037
Application Number:	63132230
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(720)489-3779
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	303-572-9300
<b>Email:</b>	kschwalbach@polsinelli.com, patentdocketing@polsinelli.com
<b>Correspondent Name:</b>	POLSINELLI PC
<b>Address Line 1:</b>	1401 LAWRENCE STREET
<b>Address Line 2:</b>	SUITE 2300
<b>Address Line 4:</b>	DENVER, COLORADO 80202
<b>ATTORNEY DOCKET NUMBER:</b>	100867-706115 (CT151-US1)
<b>NAME OF SUBMITTER:</b>	KATIE SCHWALBACH
<b>SIGNATURE:</b>	/Katie Schwalbach/
<b>DATE SIGNED:</b>	08/03/2022
<b>Total Attachments: 13</b>	

source=Executed\_Assignment#page1.tif  
source=Executed\_Assignment#page2.tif  
source=Executed\_Assignment#page3.tif  
source=Executed\_Assignment#page4.tif  
source=Executed\_Assignment#page5.tif  
source=Executed\_Assignment#page6.tif  
source=Executed\_Assignment#page7.tif  
source=Executed\_Assignment#page8.tif  
source=Executed\_Assignment#page9.tif  
source=Executed\_Assignment#page10.tif  
source=Executed\_Assignment#page11.tif  
source=Executed\_Assignment#page12.tif  
source=Executed\_Assignment#page13.tif

**ASSIGNMENT BY INVENTORS**

The undersigned Assignor Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, for good and valuable consideration paid to us by

**CRISPR THERAPEUTICS AG**

a Corporation of Zug, Switzerland, having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland, the receipt and sufficiency of which is hereby acknowledged, do hereby sell, assign, transfer and set over unto said

**CRISPR THERAPEUTICS AG**

its successors, legal representatives and assigns, the entire right, title and interest for the United States of America and all jurisdictions worldwide including all rights of priority under the Paris Convention for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the jurisdiction in which any such protection is sought in connection with subject matter including the invention or improvement in

**COMPOSITIONS AND METHODS FOR  
DIFFERENTIATING STEM CELLS INTO NK CELLS**

described in applications, in any form or embodiment thereof

☒ U.S. Application No. 63/132,230, filed on December 30, 2020

☒ U.S. Application No. 63/250,037, filed on September 29, 2021

☒ U.S. Application No. 17/538,719, filed on November 30, 2021

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all jurisdictions worldwide which may or shall be granted on or otherwise directed to said invention, or any equivalent or parts thereof or improvements now or hereafter made, or on said application, or any continuing, divisional, extension, provisional, reexamination, reissue, renewal, substitute, supplemental examination or other applications based in whole or in part thereon, and all rights to seek compensation for past infringement of said invention worldwide. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, do hereby authorize CRISPR THERAPEUTICS AG to file, or forego filing, patent applications in any jurisdictions worldwide on said invention in the name of the Assignee.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, hereby authorize the Commissioner of Patents of the United States and any authority of any jurisdiction whose duty it is to issue protections on inventions as aforesaid, to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors, legal representatives and assigns, the same to be held by Assignee for its own use and benefit and the use and benefit of its successors, legal representatives and assigns to the full end of the term or terms for which Letters Patents may be granted and/or extended.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, hereby represent and covenant that, at the time of execution and delivery of this instrument, except for any rights, titles and interests that have arisen to Assignee under law or that have already been transferred to Assignee, Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche are the lawful owners of the entire right, title and interest in and to the said inventions above-mentioned, and that the same are unencumbered and that we have good and full right and lawful authority to convey the same to Assignee in the manner herein set forth, and that Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche have not executed, and will not execute, any instrument in conflict herewith.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, further hereby agree that should any provision of this Assignment be determined to be void, invalid, unenforceable or against public policy, such provision may be altered in time or scope in order to give effect to such provision. If such alteration is not possible, such provision shall be deemed as severed from this Assignment and the remainder of this Assignment shall remain in full force and effect, so long as the original intent of this Assignment remains substantially intact.

This Assignment shall be interpreted and construed according to, and governed by, the laws of Zug, Switzerland.

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche, and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: \_\_\_\_\_

Signed: \_\_\_\_\_  
VIKTORIJA KYRYCHENKO

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche, and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: 7-22-2022

Signed: Wai Lun Leung  
WAI LUN LEUNG

Digitally signed by Wai Lun Leung  
DN: cn=Wai Lun Leung, o=CRISPR THERAPEUTICS AG, email=patrick.ovando@crispr.com, c=US  
Date: 2022.07.22 16:01:25 -0400

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche, and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: \_\_\_\_\_

Signed: \_\_\_\_\_  
PATRICK CLAUDIO OVANDO ROCHE

**ASSIGNEE:**

I hereby acknowledge that rights in the above-identified application(s) have transferred from the Assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to CRISPR THERAPEUTICS AG, the Assignee, of which I am an authorized signatory.

Date: \_\_\_\_\_

Signed: \_\_\_\_\_

SIGNATORY NAME

\_\_\_\_\_  
SIGNATORY TITLE


\_\_\_\_\_  
CRISPR THERAPEUTICS AG



DocuSign Envelope ID: 2C9632B9-66DE-4B3D-8776-DC0CF684D00A

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche,  
and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree  
to be legally bound thereby, as of the dates indicated below.

Date: 07/30/2022

Signed:   
PATRICK CLAUDIO OVANDO ROCHE

**ASSIGNMENT BY INVENTORS**

The undersigned Assignor Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, for good and valuable consideration paid to us by

**CRISPR THERAPEUTICS AG**

a Corporation of Zug, Switzerland, having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland, the receipt and sufficiency of which is hereby acknowledged, do hereby sell, assign, transfer and set over unto said

**CRISPR THERAPEUTICS AG**

its successors, legal representatives and assigns, the entire right, title and interest for the United States of America and all jurisdictions worldwide including all rights of priority under the Paris Convention for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the jurisdiction in which any such protection is sought in connection with subject matter including the invention or improvement in

**COMPOSITIONS AND METHODS FOR  
DIFFERENTIATING STEM CELLS INTO NK CELLS**

described in applications, in any form or embodiment thereof

☒ U.S. Application No. 63/132,230, filed on December 30, 2020

☒ U.S. Application No. 63/250,037, filed on September 29, 2021

☒ U.S. Application No. 17/538,719, filed on November 30, 2021

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all jurisdictions worldwide which may or shall be granted on or otherwise directed to said invention, or any equivalent or parts thereof or improvements now or hereafter made, or on said application, or any continuing, divisional, extension, provisional, reexamination, reissue, renewal, substitute, supplemental examination or other applications based in whole or in part thereon, and all rights to seek compensation for past infringement of said invention worldwide. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, do hereby authorize CRISPR THERAPEUTICS AG to file, or forego filing, patent applications in any jurisdictions worldwide on said invention in the name of the Assignee.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, hereby authorize the Commissioner of Patents of the United States and any authority of any jurisdiction whose duty it is to issue protections on inventions as aforesaid, to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors, legal representatives and assigns, the same to be held by Assignee for its own use and benefit and the use and benefit of its successors, legal representatives and assigns to the full end of the term or terms for which Letters Patents may be granted and/or extended.


And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, hereby represent and covenant that, at the time of execution and delivery of this instrument, except for any rights, titles and interests that have arisen to Assignee under law or that have already been transferred to Assignee, Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche are the lawful owners of the entire right, title and interest in and to the said inventions above-mentioned, and that the same are unencumbered and that we have good and full right and lawful authority to convey the same to Assignee in the manner herein set forth, and that Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche have not executed, and will not execute, any instrument in conflict herewith.

And Viktoriia Kyrychenko, Wai Lun Leung, and Patrick Claudio Ovando Roche, further hereby agree that should any provision of this Assignment be determined to be void, invalid, unenforceable or against public policy, such provision may be altered in time or scope in order to give effect to such provision. If such alteration is not possible, such provision shall be deemed as severed from this Assignment and the remainder of this Assignment shall remain in full force and effect, so long as the original intent of this Assignment remains substantially intact.

This Assignment shall be interpreted and construed according to, and governed by, the laws of Zug, Switzerland.

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche, and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: 07/28/22

Signed: 

VIKTORIIA KYRYCHENKO

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche, and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: \_\_\_\_\_

Signed: \_\_\_\_\_  
WAI LUN LEUNG

In witness whereof, Viktoriia Kyrychenko, Wai Lun Leung, Patrick Claudio Ovando Roche, and CRISPR THERAPEUTICS AG hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.


Date: \_\_\_\_\_

Signed: \_\_\_\_\_  
PATRICK CLAUDIO OVANDO ROCHE

**ASSIGNEE:**

I hereby acknowledge that rights in the above-identified application(s) have transferred from the Assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to CRISPR THERAPEUTICS AG, the Assignee, of which I am an authorized signatory.

Date: 02-Aug-22

Signed:  DocuSigned by:  
5F1F718513C2475...  
SIGNATORY NAME

Executive Director IP  
SIGNATORY TITLE

CRISPR THERAPEUTICS AG